StreetInsider.com News Articles

Enovix, Forte Biosciences rally premarket; PepsiCo slips

Thu, 09 Jul 2026 08:39:56 -0400

Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares.

By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.

Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.

Here are some of the biggest premarket U.S. stock movers today:

Enovix surged 17% after the battery technology company appointed former Apple executive

Enovix, Forte Biosciences rally premarket; PepsiCo slips

Thu, 09 Jul 2026 08:39:56 -0400

Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares.

By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.

Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.

Here are some of the biggest premarket U.S. stock movers today:

Enovix surged 17% after the battery technology company appointed former Apple executive

Enovix, Forte Biosciences rally premarket; PepsiCo slips

Thu, 09 Jul 2026 08:39:56 -0400

Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares.

By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.

Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.

Here are some of the biggest premarket U.S. stock movers today:

Enovix surged 17% after the battery technology company appointed former Apple executive

Enovix, Forte Biosciences rally premarket; PepsiCo slips

Thu, 09 Jul 2026 08:39:56 -0400

Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares.

By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.

Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.

Here are some of the biggest premarket U.S. stock movers today:

Enovix surged 17% after the battery technology company appointed former Apple executive

Enovix, Forte Biosciences rally premarket; PepsiCo slips

Thu, 09 Jul 2026 08:39:56 -0400

Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares.

By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.

Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.

Here are some of the biggest premarket U.S. stock movers today:

Enovix surged 17% after the battery technology company appointed former Apple executive

Enovix, Forte Biosciences rally premarket; PepsiCo slips

Thu, 09 Jul 2026 08:39:56 -0400

Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares.

By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.

Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.

Here are some of the biggest premarket U.S. stock movers today:

Enovix surged 17% after the battery technology company appointed former Apple executive

Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial

Thu, 09 Jul 2026 08:02:46 -0400

Forte Biosciences, Inc. (NASDAQ: FBRX) reported positive results from a double-blind, placebo-controlled phase 1b study of FB102 in vitiligo, according to a company statement.

The trial enrolled 43 subjects randomized 3:1, with 32 receiving FB102 and 11 receiving placebo. In the protocol-defined efficacy-evaluable population, FB102 achieved a 29.6% mean improvement from baseline in the Facial Vitiligo Area Scoring Index (FVASI) at week 24, compared to 7.9% for placebo, a placebo-adjusted benefit of 21.7% (p=0.020). Statistically significant improvement was observed as early as day 64 (p=0.023).

In subjects with greater disease involvement, defined as baseline FVASI of at least 0.75, FB102 achieved a

Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial

Thu, 09 Jul 2026 08:02:46 -0400

Forte Biosciences, Inc. (NASDAQ: FBRX) reported positive results from a double-blind, placebo-controlled phase 1b study of FB102 in vitiligo, according to a company statement.

In subjects with greater disease involvement, defined as baseline FVASI of at least 0.75, FB102 achieved a

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Thu, 09 Jul 2026 08:00:00 -0400

Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24

FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2– and IL-15–Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells

Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET

DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo:

FB102 achieved

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Thu, 09 Jul 2026 08:00:00 -0400

Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24

Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET

FB102 achieved

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Thu, 09 Jul 2026 08:00:00 -0400

Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24

Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET

FB102 achieved

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Thu, 09 Jul 2026 08:00:00 -0400

Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24

Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET

FB102 achieved

Form 4 Forte Biosciences, Inc. For: Jul 01 Filed by: Riley Antony A

Mon, 06 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26735413.html

Form 4 Forte Biosciences, Inc. For: Jul 01 Filed by: Riley Antony A

Mon, 06 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26735413.html

Form 4 Forte Biosciences, Inc. For: Jul 01 Filed by: Wagner Paul A.

Mon, 06 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260706/26735366.html

Form 4 Forte Biosciences, Inc. For: Jul 01 Filed by: Wagner Paul A.

Mon, 06 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260706/26735366.html

Form 4 Forte Biosciences, Inc. For: Jun 16 Filed by: Riley Antony A

Wed, 17 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260617/26660742.html

Form 4 Forte Biosciences, Inc. For: Jun 16 Filed by: Riley Antony A

Wed, 17 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260617/26660742.html

Form 4 Forte Biosciences, Inc. For: Jun 16 Filed by: Wagner Paul A.

Wed, 17 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260617/26660731.html

Form 4 Forte Biosciences, Inc. For: Jun 16 Filed by: Wagner Paul A.

Wed, 17 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260617/26660731.html

Forte Biosciences (FBRX) files $500M mixed shelf

Mon, 08 Jun 2026 06:04:43 -0400

Forte Biosciences (NASDAQ: FBRX) has filed $500,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Depositary Shares

Warrants

Subscription Rights

Purchase Contracts

Units

Forte Biosciences (FBRX) files $500M mixed shelf

Mon, 08 Jun 2026 06:04:43 -0400

Forte Biosciences (NASDAQ: FBRX) has filed $500,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Depositary Shares

Warrants

Subscription Rights

Purchase Contracts

Units

Forte Biosciences (FBRX) files $500M mixed shelf

Tue, 02 Jun 2026 16:43:20 -0400

Forte Biosciences (NASDAQ: FBRX) has filed $500,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Depositary Shares

Warrants

Subscription Rights

Purchase Contracts

Units

Forte Biosciences (FBRX) files $500M mixed shelf

Tue, 02 Jun 2026 16:43:20 -0400

Forte Biosciences (NASDAQ: FBRX) has filed $500,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Depositary Shares

Warrants

Subscription Rights

Purchase Contracts

Units

Form 4 Forte Biosciences, Inc. For: May 29 Filed by: Doberstein Stephen K

Tue, 02 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260602/26592465.html